Aravive (ARAV) Gets a Buy Rating from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAVResearch Report), with a price target of $25.00. The company’s shares closed last Monday at $13.52.

According to, Pantginis is a 4-star analyst with an average return of 7.7% and a 44.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Currently, the analyst consensus on Aravive is a Strong Buy with an average price target of $28.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.62 and a one-year low of $3.22. Currently, Aravive has an average volume of 486.3K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARAV in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.